• Explore /
  • Poster
  • / ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors.

ARTISTRY-3: Effect of nemvaleukin alfa with a less frequent IV dosing schedule as monotherapy and in combination with pembrolizumab and impact on the tumor microenvironment (TME) in patients (pts) with advanced solid tumors.

Abstract Poster

Authors

Sarina Piha-Paul

Sarina Anne Piha-Paul

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX

Sarina Anne Piha-Paul , Corrine F. Elliott , Yangchun Du , Julie R. Graham , Monali Desai, MD , Yan Wang , Rita P. Dalal , Nehal J. Lakhani

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04592653

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2684)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2684

Abstract #

TPS2684

Poster Bd #

331a

Abstract Disclosures

Similar Posters

First Author: Ulka N. Vaishampayan

First Author: Valentina Boni

First Author: Thomas J. Herzog

First Author: Thomas J. Herzog